Skip to main navigationSkip to main content
The University of Southampton
Southampton Health Technology Assessments CentreNews

NICE guidance informed by SHTAC report on Pembrolizumab with axitinib for untreated advanced renal cell carcinoma

Published: 5 October 2020
80% of people with kidney cancer have renal cell carcinoma

The National Institute for Health and Care Excellence (NICE) has issued guidance to the National Health Service (NHS) on the use of Pembrolizumab with axitinib for untreated advanced renal cell carcinoma, informed by a report produced by SHTAC.

NICE’s guidance does not recommend Pembrolizumab within its marketing authorisation, for untreated advanced renal cell carcinoma in adults.

Pembrolizumab with axitinib does not meet NICE's criteria to be a life-extending treatment at the end of life. The cost-effectiveness estimates are higher than what NICE normally considers an acceptable use of NHS resources. Therefore, pembrolizumab with axitinib is not recommended.

NICE’s guidance is informed by an evidence review group report prepared by SHTAC, which critically appraised the drug company’s submission to NICE’s Single Technology Appraisal process.

For more information about SHTAC’s previous research into cancer please visit our Research page.


Privacy Settings